Pharmacy Daily | Alteplase UK review

THE UK Commission on Human Medicines (CHM) will set up an expert working group to review information on use of alteplase for ischaemic stroke. This comes after the CHM considered evidence available following the extension of the treatment window for alteplase in stroke and concluded that the data did not change the balance of benefits outweighing the risks for the medication’s use and that it remained an effective medicine for treating ischaemic stroke. However it said an expert working group should be set up, to report in early 2015 on whether the evidence had implications on the risk-benefit ratio. The TGA said it would consider the CHM review and any information from the expert working group to determine whether action was required here. Boehringer Ingelheim said experts had responded to the original issues raised in the Lancet, pointing out inaccuracies, and that all data had been made available. CLICK HERE for more.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 26 Aug 14
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Aug 14